A Study to Evaluate Role of Inhaled Amikacin to Prevent Ventilator Associated Pneumonia in Patients With Cirrhosis

The recent AMIKINHAL trial found that prophylactic inhaled amikacin was effective in lowering the incidence of ventilator-associated pneumonia in ICU patients. Since aspiration is a common complication of cirrhosis patients with HE (7 out of 10 patients develop some type of HE) who are hospitalized to the liver ICU also have an elevated risk of Ventilator associated pneumonia. Despite supportive care and appropriate antimicrobial therapy pneumonia is linked to greater mortality in cirrhosis. This poses a significant challenge to physicians. Due to the lack of randomized controlled trials (RCTs) on the prophylaxis of VAP in cirrhosis patients with HE, conducting this study is necessary to evaluate the efficacy of inhaled amikacin. The study results may provide evidence -based guidance for therapy in this patient population.

NCT Number	NCT06808074
Lead Sponsor	Asian Institute of Gastroenterology, India
Conditions	Hepatic Encephalopathy, Cirrhosis, Ventilator Associated Pneumonia (VAP)
Enrollment	162 participants
Start Date	2025-02-12
Primary Completion	2026-02 (estimated)
Study Completion	2026-05 (estimated)
Updated on ClinicalTrials.gov	2025-04-04